A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors

Phase 1TerminatedNCT02045095

Millennium Pharmaceuticals, Inc.29 enrolled

Overview

The purpose of this study is to evaluate safety and tolerability (establish maximum tolerated dose \[MTD\], inform the recommended phase 2 dose \[RP2D\], and identify the dose-limiting toxicities \[DLTs\]) of MLN7243.

This is a single arm Phase I study with multiple dosing cohorts as noted below: * Schedule A: MLN7243 1 mg * Schedule A: MLN7243 2 mg * Schedule A: MLN7243 4 mg * Schedule A: MLN7243 8 mg * Schedule A: MLN7243 12 mg * Schedule A: MLN7243 18 mg * Schedule A: MLN7243 Homozygous Mutant 4 mg

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Advanced Malignant Solid Tumors

Interventions

MLN7243DRUG

Dose escalation stage Schedule A: Intravenous infusion on Days 1, 4, 8, 11 for a 21-day treatment cycle. Schedule B: Intravenous infusion on Days 1, 8, 15 for a 28-day treatment cycle. Dose expansion stage: MLN7243 will be administered following schedule A (twice-weekly, 21-day dosing) and/or B (once-weekly, 28-day dosing).

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria Each participant must meet all of the following inclusion criteria to be enrolled in the study: 1. Male or female participants 18 years or older. 2. Participants must have a histologically confirmed diagnosis of an advanced, metastatic malignant solid tumor and must have failed or exhausted standard therapies or for which no standard therapy is available. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 4. Participants with adequate hematologic and organ function. 5. All participants must have radiographically detectable tumors with measurable disease as defined by RECIST (version 1.1). 6. Participants undergoing a biopsy procedure must have accessible lesions which are safe to biopsy. 7. Recovered (that is, less than or equal to (\<=) Grade 1 toxicity) from the reversible effects of prior antineoplastic therapy, except alopecia. 8. Female participants who are postmenopausal for at least 1 year before the screening visit, surgically sterile, or agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 4 months after the last dose of study drug, or agree to practice true abstinence. Male participants who agree to practice effective barrier contraception during the entire study treatment period through 4 months after the last dose of study drug or agree to practice true abstinence. 9. Suitable venous access for the study-required blood sampling including PK sampling. Exclusion Criteria Participants meeting any of the following exclusion criteria are not to be enrolled in the study: 1. Participants with clinically significant pre-existing cardiac impairment. 2. Participants homozygous for the ABCG2 (BCRP) c.421C greater than (\>) 1 A polymorphism will be excluded from the study until the safety of a minimum of the first 3 dose levels has been characterized and the sponsor confirms that such participants can be enrolled at doses that are at least 3-fold lower than the most recently determined safe and tolerable dose among at least 3 dose limiting toxicities (DLT)-evaluable non-homozygous participants. 3. Participants with known active central nervous system (CNS) lesions are excluded. Systemic antineoplastic therapy or investigational agents within 21 days before the first dose of study drug. 4. Radiotherapy within 14 days before the first dose of study drug is not allowed except for limited field radiotherapy for palliative bone pain. 5. For participants where tumor biopsies are required or requested: * Any known coagulation abnormalities that would contraindicate the tumor biopsy procedure. * Ongoing therapy with any anticoagulant or antiplatelet agents (example, aspirin, clopidogrel \[Plavix®\], heparin, or warfarin). 6. Major surgery within 28 days before the first dose of MLN7243. 7. Life-threatening illness unrelated to cancer. 8. Any evidence of active infection or antibiotic therapy within 14 days before the first dose of MLN7243. 9. Known human immunodeficiency virus (HIV) positivity or AIDS-related illness, hepatitis B virus, and hepatitis C virus. 10. Participants whose weight is less than (\<) 40 kilogram (kg). 11. History of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness, such as severe chronic obstructive pulmonary disease. 12. Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period or a positive urine pregnancy test on Day 1 before first dose of study drug.

Locations (7)

Unnamed facility

Boston, Massachusetts, United States

Unnamed facility

St Louis, Missouri, United States

Unnamed facility

Cleveland, Ohio, United States

Unnamed facility

Philadelphia, Pennsylvania, United States

Outcomes

Primary Outcomes

Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

Time frame: Baseline up to 30 days after last dose of study drug (Cycle 10 Day 41)

Number of Participants With Laboratory Related TEAEs by System Organ Class (SOC)

Time frame: Baseline up to 30 days after last dose of study drug (Cycle 10 Day 41)

Number of Participants With Vital Sign Related TEAEs by Preferred Term (PT)

Time frame: Baseline up to 30 days after last dose of study drug (Cycle 10 Day 41)

Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities

Time frame: Cycle 1 Day 1 up to Cycle 1 Day 11

Number of Participants With Clinically Significant Echocardiogram Abnormalities

Time frame: Cycle 1 Day 2 up to 30 days after last dose of study drug (Cycle 10 Day 41)

Number of Participants With TEAEs Related to Tropinin I and T

Time frame: Baseline up to 30 days after last dose of study drug (Cycle 10 Day 41)

Secondary Outcomes

Ceoi: Plasma Concentration at the End of Infusion for TAK-243

Time frame: Cycle 1 Day 1 and 11: pre-infusion to end of infusion (up to 10 minutes)

AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-243

Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Unnamed facility

Charleston, South Carolina, United States

Unnamed facility

Nashville, Tennessee, United States

Unnamed facility

San Antonio, Texas, United States

AUCτ: Area Under the Plasma Concentration-time Curve Over the Dosing Interval for TAK-243

Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose

AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-243

Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose

CL: Total Clearance After Intravenous Administration for TAK-243

Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose

Vss: Volume of Distribution at Steady State for TAK-243

Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose

Aet: Amount of TAK-243 Excreted Unchanged in Urine

Time frame: Cycle 1 Day 1; Cycle 1 Day 11

Fet: Percentage of TAK-243 Excreted Unchanged in Urine

Time frame: Cycle 1 Day 1; Cycle 1 Day 11

Terminal Phase Elimination Half-life (T1/2) for TAK-243

Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose

Change From Baseline in Immunohistochemistry (IHC) Biomarkers in Tumor Biopsies at Cycle 1 Day 12 (C1D12) as Assessed by Histological Score (H-score)

The pharmacodynamics IHC biomarkers included polyubiquitin marker and ubquityl (Ub)-histone H2B marker. H-score was a composite score that comprised of intensity and percentage of staining and was used for assessing the amount of protein or phospho-protein present in a biopsy sample. The composite score obtained by H-score is derived by summing the percentages of cell staining at each intensity multiplied by the weighted intensity of staining (0, 1+, 2+, 3+; where 3+ indicates the strongest staining, 2+ indicates medium staining, 1+ indicates weak staining, and 0 indicates no staining). The composite H-score ranges from 0 to 300, with a score of 0 representing the absence of any of the target protein and an H-score of 300 representing maximum staining and intensity of the target protein.

Time frame: Baseline and Cycle 1 Day 12

Change From Baseline in IHC Biomarkers in Tumor Biopsies at C1D12 as Assessed by Positive Index

The pharmacodynamics IHC biomarkers included polyubiquitin marker and Ub-histone H2B marker. Positive index was calculated by taking the number of positive cells over the total number of cells.

Time frame: Baseline and Cycle 1 Day 12

Percentage of Participants With Best Overall Response

Best overall response for participant is best observed post-baseline disease response as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target and non target) must have reduction in short axis to less than (\<) 10 millimeter (mm). Partial Response (PR): at least 30 percent (%) decrease in sum of diameter of target lesions, taking as reference baseline sum of diameter. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum of diameter; PD: at least 20% increase in sum of diameter of target lesions, taking as reference, smallest sum on study (this includes baseline sum if that is smallest on study). In addition to relative increase of 20%, sum must also demonstrate an absolute increase of at least mm. The appearance of 1 or more new lesions is also considered progression.

Time frame: Baseline up to end of study (approximately 7 months)

Duration of Response

Duration of any response (CR or PR) was defined as the time (in both days and months) from the date of first documented response per the investigator response assessment to the date of first progressive disease after the first documented response or, if the participant discontinues treatment, the date of last disease assessment as per RECIST version 1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target and non target) must have reduction in short axis to \<10 mm. PR: at least 30% decrease in sum of diameter of target lesions, taking as reference baseline sum of diameter.

Time frame: Baseline up to end of study (approximately 7 months)